NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Thomas Meier's Appointment as New CEO of Medios AG
TL;DR
Medios AG appoints Thomas Meier as CEO to drive profitable growth and strengthen its position in the European Specialty Pharma market.
Thomas Meier transitions from CEO of Bachem Holding AG to lead Medios AG starting February 1, 2026, following Matthias Gaertner's departure.
Medios AG's new leadership will advance individualized medicine, making innovative therapies more accessible across Europe through specialized pharmaceutical solutions.
Thomas Meier brings international CDMO expertise from Bachem and US manufacturing experience to lead Medios AG's next development phase.
Found this article helpful?
Share it with your network and spread the knowledge!
Thomas Meier has been appointed as the new Chief Executive Officer of Medios AG, succeeding Matthias Gaertner.
Thomas Meier becomes a member of the Executive Board on February 1, 2026, and will serve as CEO from that date.
Thomas Meier has been CEO of Swiss CDMO company Bachem Holding AG since 2020, previously served as Chief Operations Officer at Bachem, and worked as Head of Manufacturing at Peninsula Laboratories in California from 2001 to 2004.
According to Dr. Yann Samson, Chairman of the Supervisory Board, Meier was selected for his international experience, strong track record of capital-efficient profitable growth, entrepreneurial spirit, expertise, and leadership capabilities.
Meier aims to lead Medios into its next development phase, consistently develop the successful strategy, and sustainably expand Medios' position in the European Specialty Pharma market.
Matthias Gaertner will remain in office until December 31, 2025, and will be succeeded by Thomas Meier effective February 1, 2026.
Medios AG is a leading provider of Specialty Pharma in Europe, focusing on pioneering individualized medicine and supporting partners in the supply chain with innovative solutions and intelligent services.
Medios AG has locations in Germany, the Netherlands, Belgium, and Spain, serving the European Specialty Pharma market.
Important dates include November 11-12 for conferences and December 4 for the Quarterly Statement as of September 30, 2025.
Contact Claudia Nickolaus, Head of Investor & Public Relations, ESG Communications at Medios AG, via phone +49 30 232 566 800 or email ir@medios.group.
Curated from NewMediaWire
